Literature DB >> 25487051

Prostate cancer: Phase I study shows potential of TRC105 in mCRPC.

Rebecca Kelsey.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25487051     DOI： 10.1038/nrurol.2014.336

Source DB:  PubMed          Journal:  Nat Rev Urol        ISSN： 1759-4812            Impact factor:   14.432


× No keyword cloud information.
  1 in total

1.  A phase I study of TRC105 anti-endoglin (CD105) antibody in metastatic castration-resistant prostate cancer.

Authors:  Fatima H Karzai; Andrea B Apolo; Liang Cao; Ravi A Madan; David E Adelberg; Howard Parnes; David G McLeod; Nancy Harold; Cody Peer; Yunkai Yu; Yusuke Tomita; Min-Jung Lee; Sunmin Lee; Jane B Trepel; James L Gulley; William D Figg; William L Dahut
Journal:  BJU Int       Date:  2015-06-08       Impact factor: 5.588
  1 in total
  2 in total

Review 1.  Targeting Met and VEGFR Axis in Metastatic Castration-Resistant Prostate Cancer: 'Game Over'?

Authors:  Alessandra Modena; Francesco Massari; Chiara Ciccarese; Matteo Brunelli; Matteo Santoni; Rodolfo Montironi; Guido Martignoni; Giampaolo Tortora
Journal:  Target Oncol       Date:  2016-08       Impact factor: 4.493

Review 2.  Endoglin in the Spotlight to Treat Cancer.

Authors:  Teresa González Muñoz; Ana Teresa Amaral; Pilar Puerto-Camacho; Héctor Peinado; Enrique de Álava
Journal:  Int J Mol Sci       Date:  2021-03-20       Impact factor: 5.923
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.